Page last updated: 2024-08-24

imiquimod and methyl 4-(adenin-9-yl)-2-hydroxybutanoate

imiquimod has been researched along with methyl 4-(adenin-9-yl)-2-hydroxybutanoate in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
He, SJ; Li, H; Lin, ZM; Liu, YT; Ma, M; Qi, Q; Shen, YF; Tang, W; Yan, YX; Yang, XQ; Zhu, FH; Zuo, JP	1

Other Studies

1 other study(ies) available for imiquimod and methyl 4-(adenin-9-yl)-2-hydroxybutanoate

Article	Year
Topical administration of reversible SAHH inhibitor ameliorates imiquimod-induced psoriasis-like skin lesions in mice via suppression of TNF-α/IFN-γ-induced inflammatory response in keratinocytes and T cell-derived IL-17. Pharmacological research, 2018, Volume: 129 Topics: Adenine; Adenosylhomocysteinase; Administration, Topical; Animals; Anti-Inflammatory Agents; Butyrates; Cells, Cultured; Cytokines; Female; Humans; Imiquimod; Keratinocytes; Mice, Inbred BALB C; Psoriasis; T-Lymphocytes	2018

Article

Year

Topical administration of reversible SAHH inhibitor ameliorates imiquimod-induced psoriasis-like skin lesions in mice via suppression of TNF-α/IFN-γ-induced inflammatory response in keratinocytes and T cell-derived IL-17.

Pharmacological research, 2018, Volume: 129

Topics: Adenine; Adenosylhomocysteinase; Administration, Topical; Animals; Anti-Inflammatory Agents; Butyrates; Cells, Cultured; Cytokines; Female; Humans; Imiquimod; Keratinocytes; Mice, Inbred BALB C; Psoriasis; T-Lymphocytes

2018